Khora Therapeutics is a clinical stage precision oncology company developing targeted therapies for cancer patients with high unmet medical needs. The company focuses on ensuring global access to these next-generation treatments, addressing disparities in healthcare availability worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer patients with specific genetic mutations do not respond well to traditional chemotherapy or radiation, leading to poor outcomes and limited treatment options. Access to targeted therapies, which address the underlying molecular drivers of their cancer, remains a challenge, particularly in underserved regions.
Solution
Khora Therapeutics is a precision oncology company focused on developing targeted therapies for cancer patients with unmet medical needs. They aim to improve treatment outcomes by creating drugs that selectively target specific genetic mutations or molecular pathways driving cancer growth. By focusing on precision medicine, Khora seeks to deliver more effective and less toxic treatments, ultimately improving the quality of life for cancer patients. Their mission includes ensuring global access to these advanced therapies, addressing disparities in healthcare availability worldwide.
Target Audience
The primary target audience includes cancer patients with specific genetic mutations who are not responding well to traditional treatments, as well as oncologists and healthcare providers seeking more effective and targeted therapies.
Features
- Development of targeted therapies designed to address specific genetic mutations in cancer cells.
- Focus on precision medicine to improve treatment outcomes and reduce side effects.
- Commitment to ensuring global access to next-generation oncology therapeutics.